Servier today announced it will present new and updated data at the 22nd International Symposium on Pediatric Neuro-Oncology (ISPNO 2026) June 28 – July 1 in Sydney, Australia. Servier’s presence at ISPNO 2026 emphasizes its advancing leadership in neuro-oncology research with the addition of OJEMDA® (tovorafenib) to its growing glioma portfolio following the recent acquisition of Day One Biopharmaceuticals.
“Our upcoming presentations at ISPNO 2026 help strengthen the robust body of evidence supporting the safety and efficacy of OJEMDA, further establishing it as a standard of care for children with relapsed/refractory pediatric low-grade glioma,” said Elly Barry, MD, Chief Medical Officer, Day One Biopharmaceuticals, now part of Servier Group. “These latest analyses from the pivotal FIREFLY-1 study – as well as the results from our caregiver survey – underscore our fierce commitment to supporting children with pediatric low-grade glioma and their caregivers, and the continued development of OJEMDA as part of Servier’s growing glioma portfolio.”
Servier will present updated three-year follow up growth recovery data from the pivotal Phase 2 FIREFLY-1 study in an oral presentation on July 1. The results suggest that most children with BRAF-altered pediatric low-grade glioma (pLGG) who experienced reduced growth velocity while being treated with OJEMDA experienced growth recovery after discontinuing treatment.
A separate analysis of the three-year follow up FIREFLY-1 data evaluating the impact of prior therapy on OJEMDA activity in BRAF-altered pLGG will also be presented in an oral presentation on July 1. Clinical benefits were observed with OJEMDA across lines of therapy, with trends toward improved durability in MAPK inhibitor-naïve patients.
Servier will also share results from a survey of pLGG caregivers about communication with their child’s diagnosing provider. Caregivers in the U.S. were invited by advocacy organizations and fellow caregivers to complete an online survey to understand caregivers’ experience of provider communication about pLGG diagnosis, including what language was used, what information was communicated, and how the approach to communication affected understanding. Data were collected using a custom-developed survey comprised of primarily closed-ended questions – scaling, yes/no, and multiple choice. This study was funded by Day One Biopharmaceuticals, a Servier Group Company.
The survey results identified both effective and suboptimal aspects of caregiver-provider communication during pLGG diagnosis and early treatment decision-making, highlighting opportunities to improve communication, strengthen trust, and increase caregiver confidence and preparedness.
Read Also: Capline Healthcare Management Cuts Claim Denials by Up to 20% With End-to-End Billing
